M. Birrell

发表

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies

Sabah Kadri, Y. L. Wang, J. Leeds, 2017, Clinical Cancer Research.

The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2a Study in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Sonali M. Smith, S. Horwitz, T. Phillips, 2018, Blood.

Preclinical Assessment of the Syk Inhibitor PRT2761 for Allergic Conjunctivitis

A. Pandey, D. Hollander, P. Gomes, 2018 .

THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR RESPONSES IN a PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES

J. Leeds, P. Hamlin, J. Curnutte, 2017 .

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Sonali M. Smith, S. Horwitz, T. Phillips, 2019, Blood.

Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B‐cell malignancies: Results of a phase I study

I. Flinn, J. Burger, J. Leeds, 2019, American journal of hematology.

The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).

Sonali M. Smith, B. Cheson, Carole B. Miller, 2018 .

Clinical and Correlative Results of a Phase 1 Study of Cerdulatinib (PRT062070) a Dual SYK/JAK Inhibitor in Patients with Relapsed/Refractory B Cell Malignancies

I. Flinn, J. Burger, J. Leeds, 2015 .